Promising Ebola Drug Fails In Clinical Trial Due To Lack Of Participants
Still, the study authors write, it came close enough to the threshold that it may shift the discussion about the virus.
Los Angeles Times:
ZMapp, Experimental Ebola Drug, Falls Short In Clinical Trial That Couldn’t Find Enough Patients
After taking a variety of factors into account, the researchers running the clinical trial calculated that there was a 91.2% chance that ZMapp made a difference for patients. That may sound impressive, but it fell short of the 97.5% threshold needed to prove that those who got the drug were more likely to survive than those who didn’t. (Kaplan, 10/13)
In other pharmaceutical news —
San Francisco Business Times:
AcelRX Pharmaceuticals Hopes To Change Pain Relief In Medical Settings
Before she started AcelRx Pharmaceuticals, Dr. Pamela Palmer had an epiphany. While on an internship at defense contractor Hughes Aircraft, the electrical engineering major realized that many of the projects were designed to kill people. She switched careers, and now works on saving and preserving lives. Her company is hard at work on products that could change pain relief. (Leuty, 10/11)